EGFR

Epidermal growth factor receptor; ErbB-1; HER1

EGFR

Related Products

The EGFR family of receptor tyrosine kinases (RTK) comprises four distinct receptors: the EGFR (also known as ErbB-1/HER1), ErbB-2 (neu, HER2), ErbB-3 (HER3) and ErbB-4 (HER4). All EGFR family members are characterized by a modular structure consisting of an extracellular ligand-binding domain, a single hydrophobic transmembrane region, and the intracellular part harbouring the highly conserved tyrosine kinase domain. The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ten growth factors and their ErbB specificities are: EGF, amphiregulin (AR), and TGF bind ErbB-1; betacellulin, and epiregulin bind both ErbB-1 and ErbB-4; the neuregulins (also called heregulins and Neu differentiation factors) NRG-1 and NRG-2 bind ErbB-3 and ErbB-4; and NRG-3 and NRG-4 bind ErbB-4. No known ligand binds ErbB-2. The three best characterized signaling pathways induced through ErbBs are Ras-mitogen-activated protein kinase (Ras-MAPK), phosphatidylinositol 3 kinase-protein kinase B (PI3K-PKB/Akt), and phospholipase C-protein kinase C (PLC-PKC) pathways.

EGFR Isoform Specific Products:

EGFR Isoform Comparison

EGFR Related Products (689)
Recombinant Proteins (77)
Antibodies (18)
EGFR Isoform Comparison

By Effects:	Inhibitors (615) Agonist (1) Degraders (10) Antagonist (1) Activators (5) Modulators (2) Chemicals (2) Inducers (4)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-13895

WHI-P154	Inhibitor	99.39%
WHI-P154 is a potent EGFR inhibitor, and also modestly blocks JAK3, with IC₅₀s of 4 nM and 1.8 μM, respectively.

HY-19803

Naquotinib mesylate	Inhibitor	98.05%
Naquotinib mesylate (ASP8273 mesylate) is an orally available, mutant-selective and irreversible EGFR inhibitor; with IC₅₀s of 8-33 nM toward EGFR mutants and 230 nM for EGFR.

HY-144880

SC209	Inhibitor	99.52%
SC209, an ADC cytotoxin extracted from patent WO2021247798, is used in synthesis of anti-EGFR antibody-drug conjugate ADC. SC209 is the payload of STRO-002.

HY-107367A

Epertinib hydrochloride	Inhibitor	98.25%
Epertinib (S-22611) hydrochloride is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR, HER4 and HER2, with IC₅₀s of 1.48 nM, 2.49 nM and 7.15 nM, respectively. Epertinib hydrochloride shows potent antitumor activity. Epertinib (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-150024

BI-4142	Inhibitor	98.39%
BI-4142 is a potent, highly selective and orally active HER2 inhibitor with an IC₅₀ of 5 nM.

HY-P9964

Necitumumab	Inhibitor
Necitumumab is a human IgG monoclonal antibody directed against EGFR. Necitumumab can be used for research of NSCLC, colorectal cancer, etc.

HY-112823B

Almonertinib hydrochloride	Inhibitor	99.77%
Almonertinib (HS-10296) hydrochloride is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib hydrochloride shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC₅₀: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib hydrochloride is used for the research of the non-small cell lung cancer.

HY-P99155

Zalutumumab		98.26%
Zalutumumab is a high affinity, completely human IgG1 monoclonal antibody targeting EGFR. Zalutumumab binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab binds with IgG and its Fab fragment with EC₅₀s of 7 and 19 nM, respectively. Zalutumumab can be used for the research of cancer.

HY-P99676

Izalontamab	Inhibitor	99.03%
Izalontamab (SI-B001) is a bispecific anti-EGFR/HER3 monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer.

HY-N2510

Myristicin	Inhibitor	99.89%
Myristicine is an orally bioavailable serotonin receptor antagonist and weak monoamine oxidase (MAO) inhibitor. Myristicine also exerts anti-cancer effects on gastric cancer cells by inhibiting the EGFR/ERK signaling pathway. Myristicine is the main component of nutmeg essential oil and has anti-cancer, anti-proliferative, antibacterial, anti-inflammatory and apoptosis-inducing effects. Myristicine abuse can produce hallucinogenic effects, organ damage, etc.

HY-17632

Tarloxotinib bromide	Inhibitor	99.26%
Tarloxotinib bromide (TH-4000) is an irreversible EGFR/HER2 inhibitor.

HY-101820

Simotinib	Inhibitor	99.39%
Simotinib is a selective, specific, and orally bioavailable EGFR tyrosine kinase inhibitor, with an IC₅₀ of 19.9 nM. Antineoplastic activities.

HY-101219

VEGFR-IN-1	Inhibitor	98.42%
VEGFR-IN-1 (compound 3) is a potent angiogenesis inhibitor with IC₅₀s of 0.02, 0.18, 0.24 7.3, and 7 µM for VEGFR2/KDR/Flk-1, Flt-1, c-Kit, EGF-R, and c-Src, respectively.

HY-B0794B

AZ7550 Mesylate	Inhibitor	99.24%
AZ7550 Mesylate is an active metabolite of AZD9291 and inhibits the activity of IGF1R with an IC₅₀ of 1.6 μM.

HY-134877

BAY 2476568	Inhibitor	99.88%
BAY 2476568 is a potent and selective EGFR inhibitor, with IC₅₀s of < 0.2 nM for wild-type EGFR and several mutations (EGFRR ex20insSVD, EGFRR ex20insASV, EGFRR ex20insNPG).

HY-135815A

Mobocertinib succinate	Inhibitor	99.83%
Mobocertinib (TAK-788) succinate is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib succinate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib succinate can be used in NSCLC research.

HY-135805A

(Rac)-JBJ-04-125-02	Inhibitor
(Rac)-JBJ-04-125-02 is the racemate of JBJ-04-125-02. JBJ-04-125-02 is a potent, mutant-selective, allosteric and orally active EGFR inhibitor.

HY-138751

limertinib	Inhibitor	99.12%
limertinib (ASK120067) is a potent and orally active inhibitor of EGFR^T790M (IC₅₀:0.3 nM) with selectivity over EGFR^WT (IC₅₀:6.0 nM). limertinib is a third-generation EGFR-TKI for the research of non-small cell lung cancer (NSCLC).

HY-157229

STX-721	Inhibitor	98.25%
STX-721 is a mutant-selective inhibitor of EGFR and HER2 Exon 20 insertion (ex20ins) mutants.

HY-107364

MTX-211	Inhibitor
MTX-211 (Mol 211) is a dual inhibitor of EGFR and PI3K with IC₅₀ values of ＜100 nM. MTX-211 can be used for the research of cancer and other diseases.

Name
Email *

	Sorry, but the email address you supplied was invalid.

EGFR

EGFR

EGFR Isoform Specific Products:

EGFR Isoform Specific Products:

EGFR Related Products (689)

Recombinant Proteins (77)

Antibodies (18)

EGFR Isoform Comparison

EGFR Related Products (689):